Yin et al. explored whether supplemental GLP-1 treatment could mitigate against these effects, and found that glomerular microvascular endothelial cells of STZ-DM rats treated with recombinant human GLP1 had diminished PKCβ activity, increased PKA activity, and an overall reduced oxidative stress burden (80). This evidence concerns the gene PRKCB and diabetes mellitus.